Our data suggested that HGF-MET signaling pathway was likely to be overactivated in ESCC, representing a potential therapeutic target, but eligibility for this therapy should consider intratumor heterogeneity. This evidence concerns the gene HGF and esophageal squamous cell carcinoma.